Fri. Nov 8th, 2024
COVID-19 Vaccination Update- Day 179
COVID-19 Vaccination Update- Day 179
COVID-19 Vaccination Update- Day 179

365telugu.com online news,India,january 22,2022:India’s COVID-19 vaccination coverage has crossed 161.81 Crore (1,61,81,65,913) today. More than 61 lakh (61,62,171) Vaccine Doseshave been administered till 7 pm today. More than 79 lakh(79,78,438) Precaution Doses for the identified categories of beneficiaries for COVID vaccination have been administered so far. The daily vaccination tally is expected to increase with the compilation of the final reports for the day by late tonight.

The cumulative coverage of vaccine doses, segregated based on population priority groups, is as follows:

Cumulative Vaccine Dose Coverage
HCWs1st Dose10391928
2nd Dose9816436
Precaution Dose2697047
FLWs1st Dose18390858
2nd Dose17131830
Precaution Dose2615336
Age Group 15-18 years1st Dose41436237
Age Group 18-44 years1st Dose533682347
2nd Dose386619600
Age Group 45-59 years1st Dose198993965
2nd Dose166043105
Over 60 years1st Dose124020921
2nd Dose103660248
Precaution Dose2666055
Cumulative 1st dose administered926916256
Cumulative 2nd dose administered683271219
Precaution Dose7978438
Total1618165913
COVID-19 Vaccination Update- Day 179
COVID-19 Vaccination Update- Day 179

Today’s achievement in the vaccination exercise, segregated by population priority groups, is as follows:

Date: 22nd January, 2022 (372ndDay)
HCWs1st Dose308
2nd Dose5529
Precaution Dose114173
FLWs1st Dose376
2nd Dose11745
Precaution Dose142797
Age Group 15-18 years1st Dose760779
Age Group 18-44 years1st Dose989118
2nd Dose2444484
Age Group 45-59 years1st Dose174302
2nd Dose725735
Over 60 years1st Dose115816
2nd Dose419916
Precaution Dose257093
Cumulative 1st dose administered2040699
Cumulative 2nd dose administered3607409
Precaution Dose514063
Total6162171
COVID-19 Vaccination Update- Day 179
COVID-19 Vaccination Update- Day 179

The vaccination exercise as a tool to protect the most vulnerable population groups in the country from COVID-19 continues to be regularly reviewed and monitored at the highest level.

error: Content is protected !!